Archive · 20 Aug 2026
Moderna Cancer Vaccine Shows Promise in Advanced Melanoma Trial
Scientists tested a cancer vaccine made specially for each patient.
The vaccine uses mRNA, a technology that gives the body instructions.
It was tested in people with advanced melanoma, a serious type of skin cancer.
The patients had already had their tumors removed with surgery.
The vaccine was given along with a medicine called Keytruda.
The results suggested that the cancer was less likely to return or spread.
Elon Musk said this kind of technology could change how diseases are treated.
However, the vaccine is not a cure for every type of cancer, and the findings only concern the melanoma patients in this trial.
Moderna and Merck reported positive Phase 3 results for intismeran autogene, an individualized mRNA vaccine for advanced melanoma.
The vaccine was tested with Merck’s immunotherapy drug Keytruda in more than 1,000 high-risk melanoma patients.
Participants had undergone surgery to remove their tumors, and the treatment helped prevent the cancer from returning or spreading.
Elon Musk said mRNA technology could make curing diseases a “software problem,” while acknowledging its misuse during COVID-19.
The results apply specifically to the melanoma trial and do not establish a universal cure for cancer.
- Who
- Moderna and Merck conducted the trial, involving more than 1,000 high-risk melanoma patients; Elon Musk and Donald Trump commented on the development.
- What
- A Phase 3 trial reported positive results for the individualized mRNA vaccine intismeran autogene combined with Keytruda.
- When
- The results were reported during the briefing described in the article; the exact date is not stated.
- Where
- The article does not specify where the trial or briefing took place.
- Why
- The treatment was developed to reduce the risk that melanoma would return or spread after surgery.
- Vaccine
- Intismeran autogene, an mRNA-based vaccine tailored to individual patients
- Cancer type
- Advanced melanoma
- Trial phase
- Phase 3
- Participants
- More than 1,000 melanoma patients considered at high risk of recurrence
- Combination treatment
- The vaccine was paired with Merck’s immunotherapy drug Keytruda
- Reported outcome
- The treatment helped stop melanoma from returning or spreading after tumor-removal surgery
- Limitation
- The findings do not show that the vaccine is a universal cure for cancer